Showing 2361-2370 of 5771 results for "".
- TopiVert Announces Publication of Data from its Positive Phase 2 Study of TOP1630 in Dry Eye Diseasehttps://modernod.com/news/topivert-announces-publication-of-data-from-its-positive-phase-2-study-of-top1630-in-dry-eye-disease/2476303/TopiVert Pharma, a clinical-stage biotechnology company developing non-systemic kinase inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular diseases, announces the publication of the
- The ASCRS Announces 2019 Ophthalmology Hall of Fame Inducteeshttps://modernod.com/news/the-ascrs-announces-2019-ophthalmology-hall-of-fame-inductees/2476313/The American Society of Cataract and Refractive Surgery (ASCRS) has announced that it will induct Howard V. Gimbel, MD, MPH, FRCSC, FACS and the late Phillips Thygeson, MD into the ASCRS Ophthalmology Hall of Fame on Saturday, May 4, 2019, according to a
- Eyenovia Announces FDA Acceptance of IND Application for MicroPinehttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-ind-application-for-micropine/2476316/Eyenovia announced that the FDA has accepted the company’s investigational new drug (IND) application to initiate the CHAPERONE study – a phase 3 registration trial of MicroPine to reduce the progression of myopia in children. “We are very pleased to have received FDA acceptance of o
- Harrow Health Announces $11 Million Series A Financing for Melt Pharmaceuticals Subsidiaryhttps://modernod.com/news/harrow-health-announces-11-million-series-a-financing-for-melt-pharmaceuticals-subsidiary/2476323/Melt Pharmaceuticals, an affiliated company of Harrow Health, announced it has entered into definitive stock purchase agreements with accredited and institutional investors to raise proceeds of approximately $11 million in a private placement sale of its Series A preferred stock at $5 per share.
- EyePoint Pharmaceuticals Announces US Commercial Launch of Yutiqhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-yutiq/2476328/EyePoint Pharmaceuticals announced the US commercially launch of Yutiq, a 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. The company has also launched EyePoint Assist, a program to ensure access to Yutiq for eligible patients in
- Johnson & Johnson Vision Announces Availability in Europe of Tecnis Eyhance IOLhttps://modernod.com/news/johnson-johnson-vision-announces-availability-in-europe-of-tecnis-eyhance-iol/2476332/Johnson & Johnson Vision announced the launch of its Tecnis Eyhance IOL in Europe. This next-generation monofocal IOL allows patients to experience high-quality vision at both intermediate and far distances. “With the availability of Tecnis Eyhance IOL in Europe, we are proud to deliv
- Founders of The Lens Butler Announce Boxsee, a New Contact Lens Subscription Servicehttps://modernod.com/news/founders-of-the-lens-butler-announce-boxsee-a-new-contact-lens-subscription-service/2476342/Beth Samenuk and Allison Granger, formerly of The Lens Butler, announced their new company and brand, Boxsee. The company represents a new vision for the future of their partnered contact lens subscription service and increases their o
- Nicox Announces FDA Acceptance of Investigational NDA for NCX 4251 Phase 2 Trial in Blepharitishttps://modernod.com/news/nicox-announces-fda-acceptance-of-investigational-nda-for-ncx-4251-phase-2-trial-in-blepharitis/2479597/Nicox SA announced that the FDA has completed its review of the company’s investigational new drug (IND) application for NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, being developed as the fi
- Bruder Announces Eyeleve Contact Lens Compresshttps://modernod.com/news/bruder-announces-eyeleve-contact-lens-compress/2479603/Bruder Healthcare announces the immediate availability of Eyeleve, a compress clinically proven to increase comfortable contact lens wear time by up to 3 hours daily. The Eyeleve Contact Lens Compress delivers consistent, therapeutic moist heat that alleviates symptoms of meibomian gland d
- FDA Commissioner Gottlieb Announces Efforts to Improve Assessment of REMS Programshttps://modernod.com/news/fda-commissioner-gottlieb-announces-efforts-to-improve-assessment-of-rems-programs/2479604/In an FDA statement, Commissioner Scott Gottlieb, MD, announced efforts to improve the quality of the information used to assess the effectiveness of Risk Evaluation and Mitigation Strategy (REMS) programs in supporting the safe use of medications. In making decisions about whether the ben